西特制药公司(West Pharmaceutical Services Inc)24日股价盘前大涨7.18%,此前公司公布的第三季度业绩优于市场预期,全年业绩预期也同步上调。
财报数据显示,该公司第三季度营收达7.469亿美元,超出分析师预期的7.096亿美元。营收主要来自专利产品部门6.014亿美元的贡献,也高于预期。经调整后,西特制药第三季度实现每股盈利1.85美元,较预期1.50美元有显著增长。
受此利好消息刺激,公司上调了2024年全年盈利预期至每股6.55-6.75美元,年营收预期上调至28.8-29.1亿美元。主要得益于全球对治疗性药物及疫苗注射设备的需求大增。公司提供了多款治疗药物如诺和诺德的减肥药物Wegovy、礼来糖尿病药Mounjaro的包装耗材。
行业分析人士指出,西特制药作为全球主要医疗包装供应商,未来发展前景广阔。伴随药品创新加快、生物制药需求持续扩张,公司营收有望保持高增长。从短期来看,业绩超预期将继续助推股价走高。中长期内,公司仍被看好为持续成长型投资标的。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.